Funktion des Immunsystems bei Leberzirrhose

Zusammenfassung

Bei Patienten mit Leberzirrhose lässt sich eine Reihe unterschiedlicher Fehlfunktionen im Immunsystem nachweisen. Diese betreffen sowohl die unspezifische Abwehr als auch die antigenspezifischen Reaktionen. Sehr gut untersucht und in seiner klinischen Bedeutung gut belegt ist die eingeschränkte Leistung des retikuloendothelialen Systems bei Leberzirrhose. Hier zeigt sich ein enger Zusammenhang zur Inzidenz bakterieller Infektionen und zur Prognose der Patienten. Andere Störungen wie die eingeschränkte Funktion neutrophiler Granulozyten sind wahrscheinlich für den klinischen Verlauf eher sekundär. Ob die gestörte Aktivierung der Natural-Killerzellen (NK-Zellen) und der lymphokinaktivierten Killerzellen (LAK-Zellen) eine Prädisposition für die Entwicklung eines hepatozellulären Karzinoms bei Leberzirrhose darstellt, müssen weitere Studien zeigen. Auffällig ist ein mäßig vermindertes Ansprechen auf Impfungen bei Leberzirrhose, was bei den meisten Impfstoffen aber durch eine Dosiserhöhung ausgeglichen werden kann.

Function of the immune system in liver cirrhosis

Malfunction of the immune system at different levels is typical for patients with liver cirrhosis. Both non-specific as well as antigen-specific functions may be compromised. The best studied and clinically most important problem is the diminished clearance capacity of the reticulo-endothelial system in liver cirrhosis. This transfers into a significantly higher rate of bacterial infections associated with a poorer prognosis in these patients. The clinical relevance of concomitant immune disorders like neutrophil dysfunction is less clear. An impaired activation of natural killer cells (NK) and lymphokine-actvated killer cells (LAK) may have a role in the development of hepatocellular carcinoma but additional studies are needed. Clinically important is a moderately reduced efficacy of standard immunization protocols, which can be overcome by an increased dose in most vaccines.

Immunsystem - Leberzirrhose - Infektionen - Makrophagen - RES - neutrophile Granulozyten - Natural-Killerzellen - Lymphozyten - Opsonine - Impfungen

Immune System - Liver Cirrhosis - Infections - Macrophages - RES - Neutrophile Granulocytes - Natural Killer Cells - Lymphocytes - Opsonines - Vaccination

Literatur

• 1 Runyon B A. Bacterial infections in patients with cirrhosis.  J Hepatol. 1993;  18 271-272
• 2 Beutler B A, Milsark I W, Cerami A. Cachectin/tumor necrosis factor: Production, distribution, and metabolic fate in vivo.  J Immunol. 1985;  135 3972-3977
• 3 Castell J V, Geiger T, Gross V. et al . Plasma clearance, organ distribution and target cells of interleukin-6/hepatocytestimulating factor in the rat.  Eur J Biochem. 1988;  177 357-361
• 4 Ferraiolo B L, Moore J A, Crase D. et al . Pharmacokinetics and tissue distribution of recombinant human tumor necrosis factor-alpha in mice.  Drug Metab Dispos. 1988;  16 270-275
• 5 Klapproth J, Castell J, Geiger T, Andus T, Heinrich P C. Fate and biological action of human recombinant interleukin 1beta in the rat in vivo.  Eur J Immunol. 1989;  19 1485-1490
• 6 Sonne O, Davidson O, Møller B K, Munck P etersen C. Cellular targets and receptors for interleukin-6: I. In vivo and in vitro uptake of IL-6 in liver and hepatocytes.  Eur J Clin Invest. 1990;  20 366-370
• 7 Wisse E, Braet F, Luo D. et al .Sinusoidal liver cells. Oxford Textbook of Clinical Hepatology, 2nd edition (Bircher J, Benhamou JP, McIntyre N, Rizetto M, Rodés J) Oxford; Oxford University Press 1999: 33-50
• 8 van Bossuyt H, de Zanger R B, Wisse E. Cellular and subcellular distribution of injected lipopolysaccharide in rat liver and its inactivation by bile salts.  J Hepatol. 1988;  7 325-327
• 9 Wisse E, Luo D, Vermijlen D. et al . On the function of pit cells, the liver-specific natural killer cells.  Semin Liver Dis. 1997;  17 265-286
• 10 McCormick P A. The spleen, hypersplenism and other relationships between the liver and the spleen. Oxford Textbook of Clinical Hepatology, 2nd edition (Bircher J, Benhamou JP, McIntyre N, Rizetto M, Rodés J) Oxford; Oxford University Press 1999: 787-795
• 11 Shah S H, Hayes P C, Allan P L, Nicoll J, Finlayson N D. Measurement of spleen size and its relation to hypersplenism and portal hemodynamics in portal hypertension due to hepatic cirrhosis.  Am J Gastroenterol. 1996;  91 2580-2583
• 12 Rozga J, Jeppsson B, Hagerstrand I, Bengmark S. Acute portal vein stenosis. An experimental study on portal circulation and hepatosplenic function.  Acta Chir Scand. 1985;  151 125-131
• 13 el-Khishen M A, Henderson J M, Millikan W J Jr, Kutner M H, Warren W D. Splenectomy is contraindicated for thrombocytopenia secondary to portal hypertension.  Surg Gynecol Obstet. 1985;  160 233-238
• 14 Mbopi-Keou F X, Belec L, Lavril M. et al . Severe lymphopenia as a predictive marker for peritoneal infection in alcoholic cirrhosis.  Eur J Med. 1992;  1 317-318
• 15 Gerok W, Rössle M, Schölmerich J. Leberzirrhose. Gerok W, Blum HE Hepatologie 2. Aufl München; Urban & Schwarzenberg 1995: 322-375
• 16 Tomino S, Fujiwara H, Kagimoto T. et al . Decreased suppressor T cell activity in patients with hepatic cirrhosis.  Clin Exp Immunol. 1982;  48 625-632
• 17 Holdstock G, Ershler  WB, Krawitt E L. Demonstration of non-specific B-cell stimulation in patients with cirrhosis.  Gut. 1982;  23 724-728
• 18 Simon G, Gorbach S L. Intestinal flora in health and disease.  Gastroenterology. 1984;  86 174-193
• 19 Lai D, Gorbach S L, Levitan R. Intestinal microflora in patients with alcoholic cirrhosis: Urea-splitting bacteria and neomycin resistance.  Gastroenterology. 1972;  62 275-279
• 20 Martini G A, Phear E A, Ruebner E, Sherlock S. The bacterial content of the small intestine in normal and cirrhotic subjects: Relation to methionine toxicity.  Clin Sci. 1956;  16 35-51
• 21 Morencos F C, de las H eras Castano G. et al . Small bowel bacterial overgrowth in patients with alcoholic cirrhosis.  Dig Dis Sci. 1995;  40 1252-1256
• 22 Yang C Y, Chang C S, Chen G H. Small-intestinal bacterial overgrowth in patients with liver cirrhosis, diagnosed with glucose H2 or CH4 breath tests.  Scand J Gastroenterol. 1998;  33 867-871
• 23 Llovet J M, Bartoli R, Planas R. et al . Bacterial translocation in cirrhotic rats. Its role in the development of spontaneous bacterial peritonitis.  Gut. 1994;  35 1648-1652
• 24 Runyon B A, Squier S, Borzio M. Translocation of gut bacteria in rats with cirrhosis to mesenteric lymph nodes partially explains the pathogenesis of spontaneous bacterial peritonitis.  J Hepatol. 1994;  21 792-796
• 25 Rimola A, Navasa M. Infections in liver disease. Oxford Textbook of Clinical Hepatology, 2nd edition (Bircher J, Benhamou JP, McIntyre N, Rizetto M, Rodés J) Oxford; Oxford University Press 1999: 1861-1874
• 26 Garcia-Tsao G, Lee F Y, Barden G E, Cartun R, West A B. Bacterial translocation to mesenteric lymph nodes is increased in cirrhotic rats with ascites.  Gastroenterology. 1995;  108 1835-1841
• 27 Sorell W T, Quigley E MM, Jin G, Johnson T J, Rikkers L F. Bacterial translocation in the portal-hypertensive rat: Studies in basal conditions and on exposure to hemorrhagic shock.  Gastroenterology. 1993;  104 1722-1726
• 28 Campillo B, Pernet P, Bories P N. et al . Intestinal permeability in liver cirrhosis: relationship with severe septic complications.  Eur J Gastroenterol Hepatol. 1999;  11 755-759
• 29 Caly W R, Strauss E. A prospective study of bacterial infections in patients with liver cirrhosis.  J Hepatol. 1993;  18 353-358
• 30 Graudal N, Milman N, Kirkegaard E, Korner B, Thomsen A C. Bacteremia in cirrhosis of the liver.  Liver. 1986;  6 297-301
• 31 Navasa M, Rimola A, Rodés J. Bacterial infections in liver disease.  Semin Liver Dis. 1997;  17 323-333
• 32 Horan T C, White J W, Jarvis W R. et al . Nosocomial infection surveillance, 1984.  Morb Mortal Wkly Rep CDC Surveill Summ. 1986;  35 17SS-29SS
• 33 EPINE W orking Group. Prevalence of hospital-acquired infection in Spain.  J Hosp Infect. 1992;  20 1-13
• 34 Dinkel R H, Lebok U. A survey of nosocomial infections and their influence on hospital morality rates.  J Hosp Infect. 1994;  28 297-304
• 35 Kuo C H, Changchien C S, Yang C Y, Sheen I S, Liaw Y F. Bacteremia in patients with cirrhosis of the liver.  Liver. 1991;  11 334-339
• 36 Deschenes M, Villeneuve J P. Risk factors for the development of bacterial infections in hospitalized patients with cirrhosis.  Am J Gastroenterol. 1999;  94 2193-2197
• 37 Runyon B A, Morrissey R L, Hoefs J C, Wyle F A. Opsonic activity of human ascitic fluid: A potentially important protective mechanism against spontaneous bacterial peritonitis.  Hepatology. 1985;  5 634-637
• 38 Runyon B A. Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis.  Gastroenterology. 1986;  91 1343-1346
• 39 Runyon B A. Patients with deficient ascitic fluid opsonic activity are predisposed to spontaneous bacterial peritonitis.  Hepatology. 1988;  8 632-635
• 40 Rimola A, Soto R, Bory F. et al . Reticuloendothelial system phagocytic activity in cirrhosis and its relation to bacterial infections and prognosis.  Hepatology. 1984;  4 53-58
• 41 Bolognesi M, Merkel C, Bianco S. et al . Clinical significance of the evaluation of hepatic reticuloendothelial removal capacity in patients with cirrhosis.  Hepatology. 1994;  19 628-634
• 42 Guarner C, Runyon B A. Macrophage function in cirrhosis and the risk of bacterial infection.  Hepatology. 1995;  22 367-369
• 43 Gomez F, Ruiz P, Schreiber A D. Impaired function of macrophage Fc-gamma receptors and bacterial infection in alcoholic cirrhosis.  New Engl J Med. 1994;  331 1122-1128
• 44 Fox R A, Dudley F J, Sherlock S. The serum concentration of the third component of complement beta-1C-beta-1A in liver disease.  Gut. 1971;  12 574-578
• 45 Kourilsky O, LeRoy C, Peltier A P. Complement and liver cell function in 53 patients with liver disease.  Am J Med. 1973;  55 783-790
• 46 Llach J, Rimola A, Navasa M. et al . Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: Relevance of ascitic fluid protein concentration.  Hepatology. 1992;  16 724-727
• 47 Tito L, Rimola A, Gines P. et al . Recurrence of spontaneous bacterial peritonitis in cirrhosis: Frequency and predictive factors.  Hepatology. 1988;  8 27-31
• 48 Altin M, Rajkovik I A, Hughes R D, Williams R. Neutrophil adherence in chronic liver disease and fulminant hepatic failure.  Gut. 1983;  24 746-750
• 49 DeMeo A N, Andersen B R. Defective chemotaxis associated with a serum inhibitor in cirrhotic patients.  New Engl J Med. 1972;  286 735-740
• 50 Feliu E, Gougerot M A, Hakim J. et al . Blood polymorphonuclear dysfunction in patients with alcoholic cirrhosis.  Eur J Clin Invest. 1977;  7 571-577
• 51 Maderazo E C, Ward P A, Quintiliani R. Defective regulation of chemotaxis in cirrhosis.  J Lab Clin Med. 1975;  85 621-360
• 52 Rajkovic I A, Williams R. Abnormalities of neutrophil phagocytosis, intracellular killing and metabolic activity in alcoholic cirrhosis and hepatitis.  Hepatology. 1986;  6 252-262
• 53 Uehara M, Sato N. Impaired ability of neutrophils to produce oxygen-derived free radicals in patients with chronic liver disease and hepatocellular carcinoma.  Hepatology. 1994;  20 326-330
• 54 Garcia-González M, Boixeda D, Herrero D, Burgaleta C. Effect of granulocyte-macrophage colony-stimulating factor on leukocyte function in cirrhosis.  Gastroenterology. 1993;  105 527-531
• 55 Yousif-Kadaru A GM, Rajkovik I A, Wyke R J, Williams R. Defects in serum attractant activity in different types of chronic liver disease.  Gut. 1984;  25 79-84
• 56 Chuang W L, Liu H W, Chang W Y. et al . Natural killer cell activity in patients with liver cirrhosis relative to severity of liver damage.  Dig Dis Sci. 1991;  36 299-302
• 57 Hirofuji H, Kakumu S, Fuji A. et al . Natural killer and activated killer activities in chronic liver disease and hepatocellular carcinoma: Evidence for a decreased lymphokine-induced activity of effector cells.  Clin Exp Immunol. 1987;  68 348-356
• 58 Nakamura T, Morizane T, Watanabe T. et al . Decreased natural killer activity in patients with liver cirrhosis.  Int J Cancer. 1983;  32 573-575
• 59 Ledesma F, Echevarria S, Casafont F, Lozano J L, Pons-Romero F. Natural killer cell activity in alcoholic cirrhosis: Influence of nutrition.  Eur J Clin Nutr. 1990;  44 733-740
• 60 Nichigaki Y, Ohnishi H, Moriwaki H, Muto Y. Ursodeoxycolic acid corrects defective natural killer activity by inhibiting prostaglandin E2 production in primary biliary cirrhosis.  Dig Dis Sci. 1996;  41 1487-1493
• 61 Shirachi M, Sata M, Miyajima I, Tanaka M, Tanikawa K. Liver-associated natural killer activity in cirrhotic rats.  Microbiol Immunol. 1998;  42 117-124
• 62 Saibara T, Maeda T, Miyazaki M, Onishi S, Yamamoto Y. Depressed immune function in patients with cirrhosis before emergence of hepatocellular carcinoma.  Hepatology. 1993;  18 315-319
• 63 Hsu C CS, Leevy C M. Inhibition of PHA-stimulated lymphocyte transformation by plasma from patients with advanced alcoholic cirrhosis.  Clin Exp Immunol. 1971;  8 749-760
• 64 Nouri-Aria K T, Alexander G JM, Portmann B C. et al . T and B cell function in alcoholic liver disease.  J Hepatol. 1986;  2 195-207
• 65 Schirren C A, Jung M C, Zachoval R. et al . Analysis of T cell activation pathways in patients with liver cirrhosis, impaired delayed hypersensitivity and other T cell-dependent functions.  Clin Exp Immunol. 1997;  108 144-150
• 66 Franco D, Charra M, Jeambrun P. et al . Nutrition and immunity after peritoneovenous drainage of intractable ascites in cirrhotic patients.  Am J Surg. 1983;  146 652-657
• 67 O’Keefe S J, El-Zayadi A R, Carraher T E, Davis M, Williams R. Malnutrition and immuno-incompetence in patients with liver disease.  Lancet. 1980;  ii 615-617
• 68 Hirsch S, de la Marza M P, Gattas V. et al . Nutritional support in alcoholic cirrhotic patients improves host defenses.  J Am Coll Nutr. 1999;  18 434-441
• 69 Keeffe E B, Iwarson S, McMahon B J. et al . Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease.  Hepatology. 1998;  27 881-886
• 70 Keeffe E B, Krause D S. Hepatitis B vaccination of patients with chronic liver disease.  Liver Transpl Surg. 1998;  4 437-439
• 71 McCashland T M, Preheim L C, Gentry-Nielsen M J. Pneumococcal vaccine response in cirrhosis and liver transplantation.  J Infect Dis. 2000;  181 757-760
• 72 Villeneuve E, Vincelette J, Villeneuve J P. Ineffectiveness of hepatitis B vaccination in cirrhotic patients waiting for liver transplantation.  Can J Gastroenterol. 2000;  14 Suppl. B 59B-62B
• 73 Wiedmann M, Liebert U G, Oesen U. et al . Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C.  Hepatology. 2000;  31 230-234
• 74 De Maria N, Idilman R, Colantoni A, Harig J M, Van Thiel D H. Antibody response to hepatitis B virus vaccination in individuals with hepatitis C virus infection.  Hepatology. 2000;  32 444-445
• 75 Dominguez M, Barcena R, Garcia M, Lopez-Sanroman A, Nuno J. Vaccination against hepatitis B virus in cirrhotic patients on liver transplant waiting list.  Liver Transpl. 2000;  6 440-442
• 76 Horlander J C, Boyle N, Manam R. et al . Vaccination against hepatitis B in patients with chronic liver disease awaiting liver transplantation.  Am J Med Sci. 1999;  318 304-307